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ABSTRACT
The epidemiological impact of Acinetobacter baumannii nosocomial infections in a Sicilian intensive care
unit (ICU) was investigated to determine the Acinetobacter-specific infection rates, to estimate the
preventable proportion of Acinetobacter infections, i.e., those resulting from cross-transmission, and to
investigate the molecular epidemiology of antimicrobial resistance in Acinetobacter. The impact of
Acinetobacter nosocomial infection in the ICU was determined to be 3.0 new cases per 100 admissions. Site-
specific rates confirmed that ICU-acquired pneumonia was the most important infection type. The
incidence rate, adjusted by the number of patient-days, was 3.3 infections ⁄ 1000 patient-days. The
estimated preventable proportion of A. baumannii nosocomial infections in the ICU was 66.7%. A class 1
integron, characterised by its gene cassette content, was present in allA. baumannii isolates of four different
pulsed-field gel electrophoresis types, and was associated significantly with clones implicated in cross-
transmission episodes. Furthermore, the same integron was detected in two genetically distinct isolates
responsible for recurrent infection in the same patient, suggesting the occurrence of horizontal gene
transfer in vivo. Even in an endemic setting with low infection rates, spread of A. baumannii was caused
mainly by infection control shortcomings that require appropriate surveillance and control policies.
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INTRODUCTION
Epidemiological surveillance is a critical and
essential element of any successful infection
control programme and is especially recommend-
ed in intensive care units (ICUs) in order to
increase awareness and to identify areas for
improvement. ICU patients are at five- to ten-fold
greater risk of acquiring a nosocomial infection,
and the ICU is often the epicentre of emerging
infection problems in a hospital [1].
Multiresistant Acinetobacter spp. have become
established as ‘alert’ nosocomial pathogens,
particularly in ICUs, and are associated with
outbreaks of nosocomial infection, often attribut-
able to medical equipment and materials that may
have had contact with water of uncertain quality,
as well as dry environmental surfaces [2].
Although the genus Acinetobacter currently com-
prises at least 32 different species, with many as
yet unclassified strains, Acinetobacter baumannii is
reported most frequently among epidemic iso-
lates [3,4]. Nosocomial infections caused by
A. baumannii are difficult to treat because of the
multiple antibiotic resistance of this species.
Studies of antibiotic resistance mechanisms in
A. baumannii strains have demonstrated the pres-
ence of specific genes located on integrons, and
molecular typing studies have shown that type 1
and type 2 integrons bearing antimicrobial resist-
ance genes are often associated with epidemic
clones [5,6].
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Microbial transmission may occur via the
endogenous route (i.e., a patient’s own flora)
or via the exogenous route (e.g., a healthcare
worker’s hands or equipment). Therefore, it is
important to determine whether infections are
attributable to the severity of the patient’s
illness, or whether they are caused by infection
control shortcomings that result in cross-trans-
mission within a unit [7]. Although various risk-
factors predisposing to infection with Acineto-
bacter spp. have been identified, including pre-
vious antimicrobial therapy that alters the
normal flora and results in the selection of
resistant Acinetobacter strains, cross-transmission
and the hospital environment are probably the
most likely sources of this organism [3,8].
Ideally, the diagnostic laboratory should be
involved in active surveillance, providing sys-
tematic observation and measurement of dis-
ease, as well as molecular typing of microbial
pathogens [9]. Epidemiological typing may
enable conclusions to be reached concerning
the possible prevention of exogenous infections
through infection control measures. However,
although this approach has been used fre-
quently in outbreak investigations, it has been
used less frequently for surveillance studies
under endemic conditions.
To date, there have been few surveillance
studies of Acinetobacter nosocomial infections in
Italy [6,10]. In the ICU of a Sicilian hospital, the
Azienda Ospedaliera S. Giovanni di Dio, Agrig-
ento, Acinetobacter spp. were found only sporad-
ically before 2001. The subsequent observation in
the ICU of A. baumannii infections, with neither
an evident common source nor a linked chain of
transmission, prompted a prospective investiga-
tion to determine the rates of A. baumannii-asso-
ciated infections. The present study was designed
to evaluate the epidemiological impact of A. bau-
mannii nosocomial infections in the ICU through a
unit-based surveillance, using the Hospitals in
Europe Link for Infection Control through Sur-
veillance (HELICS) protocol [1]. The specific aims
of the study were: (1) to determine the Acineto-
bacter-specific infection rates within the ICU;
(2) to estimate the preventable proportion of
Acinetobacter infections; and (3) to characterise
the integron contents and sequences of the
strains involved in order to investigate the
molecular epidemiology of antimicrobial resist-
ance in Acinetobacter.
MATERIALS AND METHODS
Nosocomial infection surveillance methods
Between November 2001 and February 2004, all 665 patients
admitted to the ten-bed combined surgical and medical ICU of
the Azienda Ospedaliera S. Giovanni di Dio, a 339-bed
hospital, were enrolled into the laboratory-based alert surveil-
lance, performed by trained personnel using a unit-based
protocol for continuous surveillance. Infection data were
collected for each episode of Acinetobacter infection with onset
within the surveillance period. The number of new admissions
and the number of patient-days for patients staying >2 days in
the ICU were also collected. Acinetobacter-associated infections
were identified using standard definitions [1]. If the infection
criteria were not met, colonisation was defined by the presence
of Acinetobacter in clinical specimens. Surveillance data were
analysed using SPSS v. 11.0 (SPSS Inc., Chicago, IL, USA).
Bacterial isolates
In total, 25 Acinetobacter isolates from 22 patients (17 from the
ICU, two from orthopaedics, one from the medical ward, one
from paediatrics and one from the neonatal ICU) were obtained
from clinical specimens and identified presumptively by stand-
ard methods (ID 32 GN; bioMe`rieux, Marcy l’Etoile, France).
Antimicrobial susceptibilities
Antimicrobial resistance was determined by the NCCLS disk-
diffusion method [11]. Isolates showing an intermediate level
of susceptibility were classified as resistant. If isolates were
resistant to imipenem and meropenem by disk-diffusion, the
imipenem MIC and the presence of metallo-b-lactamase (MBL)
activity were determined with Etest MBL strips (AB Biodisk,
Solna, Sweden), as described previously [12].
Genotypic identification
The genomic species of each Acinetobacter isolate was deter-
mined by Tsp509I restriction analysis of an amplified internal
sequence of the recA gene as described previously [13]. In brief,
crude template DNA was prepared by suspending two to
three colonies from an overnight agar plate in 100 lL of ultra-
pure water, heating to 95C for 15 min to lyse the cells, cooling
on ice and centrifuging for 20 s at 12 000 g to remove cell
debris [14]. PCR amplification of the recA gene was performed
using forward primer rA1 and reverse primer rA2 [13]. PCRs
contained 200 lM dNTPs, 0.5 lM each primer, 0.2 lg of target
DNA and 2.5 U of DNA polymerase in a total volume of 50 lL.
PCRs comprised 35 cycles of 94C for 1 min, 57C for 1 min
and 72C for 2 min; amplified products were visualised
following electrophoresis on agarose 1% w ⁄v gels. Amplified
DNA (10 lL) was digested for 2 h at 65C in a 25-lL volume
with Tsp509I. Digested samples were electrophoresed in a
polyacrylamide 12% w ⁄v gel. Tsp509I restriction fragment
length polymorphism (RFLP) profiles were compared with
representative patterns of known genomic species [13].
Macrorestriction analysis
Molecular typing by pulsed-field gel electrophoresis (PFGE) of
ApaI-digested genomic DNA was performed as described
previously [15]. In brief, isolates were grown overnight on
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nutrient agar, suspended in 3 mL of SE buffer (75 mM NaCl,
25 mM EDTA, pH 7.5) and adjusted to a density equivalent to a
2· McFarland standard. Cells were washed twice with 3 mL of
SE buffer before being resuspended finally in 1 mL of SE buffer.
Cell suspensions were mixed with an equal volume of low-
melting-point agarose 2%w ⁄v and pipetted into a plug mould.
Plugs were allowed to solidify for 5 min at) 20C, and were then
lysed at 56C overnight with proteinase K 1 mg ⁄mL. Digestion
with ApaI (30 U ⁄plug) was performed at 25C for 5 h. Macro-
restriction fragments were separated with a CHEF-DR III
apparatus (Bio-Rad Laboratories, Hercules, CA, USA) at 8C
for 20 h, with an initial pulse time of 5 s and an end pulse time of
13 s, at 6 V ⁄ cm. A concatamer ladder of lambda phage DNA
was used as a size marker. Interpretation of genomic relatedness
was performed using well-established criteria [16]. Isolates with
patterns that differed by two or three fragments were considered
to be subtypes of the same clone; different, although possibly
related, clones were defined as those showing at least four DNA
fragment differences; patterns that differed by seven or more
fragments were considered to be unrelated.
Characterisation of class 1 integrons and
metallo-b-lactamase genes
PCR amplification of class 1 integrons and mapping of
resistance genes were performed with 0.5 lg of genomic
DNA as described previously [17]. Primers for the detection of
class 1 integrons were located in the 5¢-conserved segment (CS)
and in the 3¢-CS [5]. Detection of class 1 and class 2 integrons
by integrase gene PCR was performed as described by
Koeleman et al. [5]. PCR products were purified by low-
melting-point agarose gel electrophoresis, phenol–chloroform
extraction and ethanol precipitation, and were then sequenced
(see below). PCR analysis of blaIMP-like or blaVIM-like genes
was performed with degenerate primers as described by
Nordmann and Poirel [18].
DNA sequencing
Cycle sequencing of purified PCR products was performed
with the ABI PRISM BigDye Terminator v. 3.0 Ready Reaction
Cycle Sequencing Kit as recommended by the manufacturer
(Applied Biosystems, Foster City, CA, USA). DNA products
were analysed with an AB 3100 Genetic Analyser (Applied
Biosystems). Similarity searches of the DNA sequences
obtained were performed with the BLAST program against
nucleic acid sequence databases.
Identification of episodes of cross-transmission
The presence of two indistinguishable strains in two patients
was considered to represent one episode of cross-transmission.
In general, the number of cross-transmissions that occurred in
a ward was calculated by subtracting 1 from the number of
indistinguishable strains in different patients [7].
RESULTS
Nosocomial infection surveillance
Of the 25 Acinetobacter spp. isolates collected, 20
were associated with infections of ICU patients:
13 with ICU-acquired pneumonia, five with urin-
ary tract infections (UTIs) and two with blood-
stream infections. Three isolates were associated
with infections acquired outside the ICU: one
surgical site infection in an orthopaedic patient,
and two UTIs (one each in a medical and an
orthopaedic patient). Finally, two isolates, one
from a neonatal ICU patient and one from a
paediatric patient, were classified as colonising
isolates. All 25 clinical isolates were identified
presumptively as A. baumannii by phenotypic
characterisation.
There were 3.0 new Acinetobacter infections ⁄ 100
admissions to the ICU (20 infections and 665
admissions). Of these, 65% were ICU-acquired
pneumonia, 25% were UTIs, and 10% were
bloodstream infections. The incidence rate, adjus-
ted by the number of patient-days, was 3.5
infections ⁄ 1000 patient-days (20 infections and
5675 patient-days). Site-specific rates were 2.3%
for ICU-acquired pneumonia, 0.9% for UTIs, and
0.3% for bloodstream infections.
Genotypic identification
Genomic species identification was performed by
Tsp509I RFLP analysis of the amplified internal
sequence of the recA gene. This method confirmed
the biochemical identification of 21 (84%) isolates,
including 19 isolates from ICU patients and
two isolates from orthopaedic patients, as Acine-
tobacter genomic sp. 2, i.e., A. baumannii. Four
(16%) isolates were misidentified with standard
identification methods: one (4%) isolate failed to
give any amplification product, leaving this strain
unidentified by the recA-based assay, while the
other three (12%) isolates, one each from the
neonatal ICU, the paediatric ward and the med-
ical ward, gave identical patterns that did not
match with any known reference profile [13]. The
amplicons obtained from these three isolates were
sequenced and shown to have homology
with the recA gene of Acinetobacter genomic sp. 3
(Table 1).
Thus, following genotypic identification, the
final A. baumannii infection rate in the ICU was
3.3% (19 infections and 5675 patient-days).
Macrorestriction analysis
Macrorestriction analysis of the Acinetobacter iso-
lates identified eight unrelated PFGE types,
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named A–H. Six PFGE types were single patterns
associated with sporadic isolates; the remaining
two A. baumannii PFGE types were associated
with cross-transmission of infection. Type B was
common to four isolates from four patients in the
ICU, and type C was common to 12 isolates from
ten patients in the ICU, and by two isolates from
two patients in the orthopaedic ward (Table 1).
No PFGE profile was obtained for the isolate that
failed to give a PCR amplification product. The
occurrence of two infections (ICU-acquired pneu-
monia and UTI) was associated with PFGE type C
in two patients. Two serial isolates from the same
patient showed two distinct macrorestriction
patterns; the first isolate belonged to PFGE type
B, while an isolate with the unrelated sporadic
type D profile was identified 1 month later.
Antimicrobial susceptibility patterns
Analysis of antimicrobial susceptibility patterns
showed that Acinetobacter isolates with different
PFGE profiles all had a multiresistant antibiotype
characterised by resistance to monobactams and
ceftriaxone, and resistance or intermediate
susceptibility to piperacillin–tazobactam, broad-
spectrum cephalosporins, aminoglycosides,
ciprofloxacin and trimethoprim–sulphamethoxaz-
ole (Table 2). Seven of eight Acinetobacter PFGE
types were susceptible to ampicillin–sulbactam
and carbapenems, and all Acinetobacter PFGE
types were susceptible to colistin. A. baumannii
isolates of PFGE type C were resistant to most
antimicrobial agents, but were sensitive to
ampicillin–sulbactam, carbapenems and colistin.
A. baumannii isolates of PFGE type B were
characterised by resistance to most of the
antimicrobial agents tested, including ampicil-
lin–sulbactam, but all type B isolates were sus-
ceptible to colistin, and three of four isolates were
susceptible to carbapenems (Table 2). With this
single exception, all Acinetobacter isolates with the
same PFGE profile had the same antibiotype.
MICs of imipenem and MBL activity were
determined for all A. baumannii isolates belonging
to PFGE type B. Three isolates were susceptible to
imipenem (MIC < 4 mg ⁄L) and negative for MBL
production (imipenem + EDTA MIC < 1 mg ⁄L),
while one isolate was resistant to imipenem (MIC
16 mg ⁄L) and negative for MBL production
(imipenem + EDTA MIC 4 mg ⁄L). No amplifica-
tion products were obtained from these four
isolates with PCRs specific for blaIMP-type or
blaVIM-type carbapenemase genes (data not
shown).
Identification of class 1 integrons in
Acinetobacter isolates
Single amplification products of c. 2.2 kb were
obtained from the chromosomal DNA of all the
A. baumannii isolates belonging to PFGE types B,
C, D and F, using primers corresponding to the
conserved regions of type 1 integrons [17]. No
amplification products were obtained from the
sporadic isolates belonging to PFGE types A, E, G
and H, and no amplicon was obtained from the
unidentified isolate (Table 1). Sequence analysis
of the integrons from PFGE types B, C, D and F
demonstrated a 2230-bp amplicon containing
Table 1. Molecular epidemiology of Acinetobacter isolates
included in the study
Number of isolates
and ward of isolation
Associated
infections (n)
recA-based
identification
PFGE
type
Class 1
integron
1 (ICU) UTI (1) A. baumannii A Absent
4 (ICU) P (4) A. baumannii B 2.2 kb
12 (ICU) P (8), UTI (4) A. baumannii C 2.2 kb
2 (OW) UTI (1), SSI (1) A. baumannii C 2.2 kb
1 (ICU) P (1) A. baumannii D 2.2 kb
1 (MW) UTI (1) Acinetobacter sp. 3 E Absent
1 (ICU) BSI (1) A. baumannii F 2.2 kb
1 (NICU) Col (1) Acinetobacter sp. 3 G Absent
1 (PW) Col (1) Acinetobacter sp. 3 H Absent
1 (ICU) BSI (1) Unidentified ND Absent
ICU, intensive care unit; OW, orthopaedics ward; MW, medical ward; NICU,
neonatal intensive care unit; PW, paediatric ward; UTI, urinary tract infection; P,
ICU-acquired pneumonia; SSI, surgical site infection; BSI, bloodstream infection;
Col, colonisation; ND, not determined.
Table 2. Antimicrobial susceptibility patternsa of Acineto-
bacter PFGE types
Antimicrobial agent
PFGE types
A B C D E F G H
Ampicillin–sulbactam s r s s s s s s
Piperacillin r r r r s r s s
Piperacillin–tazobactam r r r s s s s s
Cefepime r r r r s s s s
Ceftazidime r r r r s s s s
Ceftriaxone r r r r r r r r
Aztreonam r r r r r r r r
Imipenem s s ⁄ r s s s s s s
Meropenem s s ⁄ r s s s s s s
Amikacin r r r r s s s s
Gentamicin s r r r s s s s
Netilmicin r r r r s r s s
Tobramycin s r r s s s s s
Ciprofloxacin r r r r s s s s
SXT s r r s s s s s
Colistin s s s s s s s s
PFGE, pulsed-field gel electrophoresis; SXT, trimethoprim–sulphamethoxazole; s,
susceptible; r, resistant.
aAntimicrobial resistance was determined by the disk-diffusion method. Isolates
showing an intermediate level of susceptibility were classified as resistant.
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three gene cassettes: an aacA4 allele encoding
an AAC(6¢)-Ib aminoglycoside acetyltransferase
conferring resistance to amikacin, netilmicin and
tobramycin; an open reading frame coding for
an unknown product; and blaOXA-20, a gene
encoding a class D b-lactamase conferring resist-
ance to amoxycillin, ticarcillin, oxacillin and
cloxacillin.
The presence of integrons in the Acinetobacter
isolates was also investigated by integrase gene
PCRs specific for the intI1 and intI2 genes [5].
Class 1 integrons were detected in all A. bauman-
nii isolates belonging to PFGE types B, C, D and F,
but not in PFGE types A, E, G and H. Class 2
integrons were not detected in any of the Acine-
tobacter isolates (data not shown).
Identification of cross-transmission episodes
and association with class 1 integron sequences
There were 14 episodes of cross-transmission,
accounting for 66.7% of all A. baumannii nosoco-
mial infections (14 of 21 infections). The presence
of class 1 integron sequences (n = 20) was shown
to be statistically significant (p < 0.001) in isolates
(n = 18) involved in episodes of cross-transmis-
sion.
DISCUSSION
The proportion of potentially preventable nosoco-
mial infections has been addressed recently by a
systematic review of the published literature
describing multi-modal intervention studies and
transmission studies performed during the last
decade [19]. It was concluded that ‡ 20% of all
nosocomial infections are probably avoidable, but
that further research into the feasibility and cost-
effectiveness of prevention is required. Few stud-
ies have addressed the issue of estimating the
preventable proportion of nosocomial infections
under routine conditions [19,20], and there are
even fewer reports concerning ICU-acquired
infections caused by Acinetobacter spp. in Italy
[6,10]. The present study was designed to assess
the preventable proportion of infections caused
by Acinetobacter in a Sicilian hospital by means of
a unit-based surveillance protocol. Although indi-
cators generated by such a ‘first-level’ surveil-
lance are not suitable for ICU benchmarking of
quality of care in terms of infection control, they
are appropriate for the follow-up of infections
within the same unit and for regional, national
and international investigation of trends for
pathogen-specific infection rates [1].
In total, 23 of 25 isolates were associated with
infection, which was a rather high proportion,
since Acinetobacter isolates have been reported to
be associated most frequently with colonisation
[21]. Although the relevance of patient colonisa-
tion in the epidemiology of A. baumannii is well-
known [3,22], the incidence of infection vs.
colonisation may vary among wards, or even
within the same ward, at different times [6,23].
Possible explanations for the high infection-to-
colonisation ratio in this ICU include different
criteria for submission of clinical specimens for
microbiological culture, and utilisation of the
HELICS definitions for infections, particularly
those for nosocomial pneumonia; the latter are
based on draft CDC criteria that have recently
been reported to be in better agreement with
clinical assessment than the current CDC defini-
tions [24].
The impact of Acinetobacter nosocomial infec-
tions in the ICU was 3.0 new cases ⁄ 100 admis-
sions, which is a relatively low rate when
compared with epidemic rates reported in the
literature, e.g., 14% in Spain [25] and 12.4% in
Italy [10]. Site-specific rates showed that ICU-
acquired pneumonia is the most important type
of Acinetobacter infection, as reported previously
[6,10]. The incidence rate of 3.3 A. baumannii
infections ⁄ 1000 patient-days was lower than the
pooled rate of 4.5 A. baumannii colonisations or
infections ⁄ 1000 patient-days reported in a multi-
centre study of Spanish ICUs [23]. The present
alert surveillance study estimated the preventable
proportion of A. baumannii nosocomial infections
in the ICU as 66.7%. Thus, exogenous transmis-
sion may be considered as a major infection
control problem, even in a ward with low baseline
rates, indicating that there is still scope for
improvement and that the preventive potential
is even higher than the figure of 20% determined
previously [19].
Commercial identification systems have a
limited capability to differentiate Acinetobacter
genomic species [26]. A variety of genotypic
methods have been explored for species identifi-
cation, including a rapid method based on recA
PCR Tsp509I RFLP analysis that has been shown
to be suitable for continuous epidemiological
surveillance surveys [13]. Nevertheless, some
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limitations were observed in the present study:
three isolates, identified presumptively as A. bau-
mannii, were excluded as such, but further
sequencing was necessary to assign them defin-
itively to Acinetobacter genomic sp. 3. Further-
more, recA amplification failed for one isolate,
identified consistently as A. baumannii in repeated
biochemical assays. Therefore, the recA-based
method was not as useful as amplified rDNA
restriction analysis, a thoroughly validated geno-
typic identification assay, for which a compre-
hensive database has been established [27,28].
Acinetobacter spp. have become resistant to
almost all antimicrobial agents that are currently
available, including the aminoglycosides, quino-
lones and broad-spectrum b-lactams [29], and all
the Acinetobacter PFGE types isolated in this study
had multiresistant antibiotypes. In particular,
A. baumannii isolates of PFGE type B were resist-
ant to most of the antimicrobial agents tested,
with the exception of colistin for all isolates and
carbapenems for three isolates. A. baumannii iso-
lates of PFGE type C were also resistant to most of
the antimicrobial agents tested, but were sensitive
to ampicillin–sulbactam, carbapenems and colis-
tin. A. baumannii nosocomial acquisition has
been associated previously with elevated rates
of resistance to broad-spectrum cephalosporins,
carbapenems and aminoglycosides in ICUs [6].
Additional epidemiological data were provided
by molecular typing of the A. baumannii isolates. A
class 1 integron, characterised by the same set of
gene cassettes, was present in all A. baumannii
isolates belonging to PFGE types B, C, D and F, and
was associated significantly with isolates involved
in episodes of cross-transmission. This is in agree-
ment with previous studies demonstrating that
integrons bearing antimicrobial resistance genes
are found in the genome of epidemic A. baumannii
strains [5,6]. The presence of integrons with the
same molecular organisation in A. baumannii iso-
lates belonging to different PFGE types suggests
that horizontal gene transfer of integrons may have
occurred [5,30,31]. In the present study, the same
integron was detected in two unrelated isolates
responsible for sequential infection in the same
patient. Thus, in-vivo horizontal gene transfer may
have been selected by the antimicrobial therapy
prescribed for a patient in an ICU where epidemic
and sporadic clones co-exist.
Even in an endemic setting with low infection
rates, A. baumannii spread occurs mainly as a
result of cross-infection problems that require
appropriate surveillance and infection control
policies [20]. Although the present study was
not designed to identify risk-factors, there was no
adequate infection control programme at the time
of the study. Cross-transmission may have
occurred via inadequate decontamination of
patient-care equipment [3,8], poor hand hygiene
and insufficient routine cleaning of clinical areas
[32]. Feedback of surveillance data to healthcare
personnel, including molecular typing data of
bacterial isolates and their associated antibiotic
resistance genes, is essential to prevent horizontal
transmission [9,33]. A molecular-based approach
to the control of Acinetobacter nosocomial infec-
tions would provide an insight into the popula-
tion dynamics of bacterial circulation in the
hospital setting, and would allow the design of
evidence-based strategies to decrease specific
infection rates to the irreducible minimum.
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